Skip to main content

Table 1 Baseline characteristics of studies included in the network meta-analysis

From: Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

Study Size Age Male (%) Reported outcomes Interventional arm Control arm
First-line (n = 5)
 Checkmate648 321/325/324 64/63/64 79/83/85 OS; PFS; ORR; Grade ≥ 3 AEs Nivolumab 240 mg every 2 weeks plus chemotherapy (PF) chemotherapy alone (Fluorouracil: 800 mg mg/m2 on days 1–5 plus cisplatin: 80 mg/m2 on days 1 for every 4 weeks)
    OS; ORR; Grade ≥ 3 AEs Nivolumab (3 mg per kilogram every 2 weeks) plus Ipilimumab (1 mg per kilogram every 6 weeks)
 ESCORT-1st 298/298 62/62 87/88 OS; PFS; Grade ≥ 3 AEs Camrelizumab 200 mg every 3 weeks plus chemotherapy (TP) Placebo plus chemotherapy (Paclitaxel: 175 mg/m2 plus cisplatin: 75 mg/m2 on day 1 for every 3 weeks)
 KEYNOTE 590 274/274 64/62 82/85 OS; PFS; ORR; Grade ≥ 3 AEs Pembrolizumab 200 mg every 3 weeks plus chemotherapy (PF) Placebo plus chemotherapy (Fluorouracil: 800 mg/m2 on
days 1–5 plus cisplatin: 80 mg/m2 on day 1 for every 3 weeks)
 JUPITER-06 257/257 63/62 84/86 OS; PFS; ORR; Grade ≥ 3 AEs Toripalimab 240 mg every 3 weeks plus chemotherapy (TP) Placebo plus chemotherapy (Paclitaxel: 175 mg/m2 plus cisplatin: 75 mg/m2 on day 1 for every 3 weeks)
 ORIENT-15 327/322 / / OS; PFS; ORR; Grade ≥ 3 AEs Sintilimab 200 mg every 3 weeks plus chemotherapy (TP or PF) Placebo plus chemotherapy (Paclitaxel: 87.5 mg/m2 on day 1, 8 or 175 mg/m2 on day 1 plus cisplatin:75 mg/m2 on day 1; or fluorouracil: 800 mg/m2 on days 1–5 plus cisplatin:75 mg/m2 on day 1)
Second-line (n = 5)
 ATTRACTION-3 210/209 64/67 85/89 OS; PFS; ORR; Grade ≥ 3 AEs Nivolumab 240 mg given every 2 weeks. Investigator’s choice of chemotherapy (Paclitaxel 100 mg/m2 per week or docetaxel 75 mg/m2 every 3 weeks)
 ESCORT 228/220 60/60 91/87 OS; PFS; ORR; Grade ≥ 3 AEs Camrelizumab 200 mg given every 2 weeks. Investigator’s choice of chemotherapy (Docetaxel 75 mg/m2 every 3 weeks or irinotecan180 mg/m2 every 2 weeks)
 KEYNOTE-181 314/314 63/62 86.9/86.3 OS; PFS; ORR; Grade ≥ 3 AEs Pembrolizumab 200 mg given every 3 weeks. Investigator’s choice of chemotherapy (Paclitaxel 80–100 mg/m2 every 4 weeks, docetaxel 75 mg/m2 every 3 weeks or irinotecan 180 mg/m2 every 2 weeks)
 RATIONALE 302 256/256 62/63 84.8/84.0 OS; ORR; Grade ≥ 3 AEs Tislelzumab 200 mg given every 3 weeks. Investigator’s choice of chemotherapy (Paclitaxel 135–175 mg /m2 every 3 weeks, docetaxel 75 mg/m2 every 3 weeks or irinotecan 125 mg/m2 every 3 weeks
 ORIENT-2 95/95 59/59 92.6/88.4 OS; PFS; ORR; Grade ≥ 3 AEs Sintilimab 200 mg given every 3 weeks. Investigator’s choice of chemotherapy (Paclitaxel 175 mg/m2 every 3 weeks or irinotecan 180 mg/ m2 every 2 weeks)
  1. Abbreviations: OS Overall survival, PFS Progression-free survival, ORR Overall response rate, AEs Adverse events, PF Fluorouracil and cisplatin, TP Paclitaxel and cisplatin